Navigation Links
ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011

RANCHO CORDOVA, Calif., Sept. 6, 2011 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal fourth quarter and full year ended June 30, 2011, on Monday, September 12, 2011.

Company's Conference Call and Webcast

Management will host a conference call Monday, September 12, 2011 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal fourth quarter and fiscal year end financial results.  

The call can be accessed by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing, "ThermoGenesis." Mr. J. Melville Engle, Chairman and Chief Executive Officer and Mr. Matthew Plavan, Chief Financial Officer and Executive Vice President, Business Development will host the call to discuss the year end, quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately five minutes before the conference call begins.  

To listen to the audio webcast of the call during or after the event, please visit:


A replay of the conference call will be available two hours after the call for the following five business days by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and entering the following account number when prompted '385107'.

About ThermoGenesis Corp.

ThermoGenesis Corp. ( is a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury.

This press release contains forward-looking statements.  These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2011 and 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2011 and 2012.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site:
Contact: Investor Relations
+1-916-858-5107, or

SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ThermoGenesis Announces China Customer Implements Cord Blood Products
2. ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
3. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
4. Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009
5. ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
6. ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
7. ThermoGenesis Announces Expanded Collaboration With Celling Technologies
8. ThermoGenesis Provides Update on Fiscal 2009 Results
9. ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference
10. ThermoGenesis Says FDA Concurs with Plan for Previously Announced AXP(TM) Bagset Recall
11. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> Accutest Research Laboratories, ... Contract Research Organization (CRO), has formed ... Cancer Center - Temple Health for ... ,     (Photo: ) , ...
(Date:11/25/2015)... November 25, 2015 2 nouvelles études ... les différences entre les souches bactériennes retrouvées dans ... des êtres humains . Ces recherches  ouvrent une ... la prise en charge efficace de l,un des ... les chats .    --> 2 nouvelles ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
Breaking Biology Technology:
(Date:11/16/2015)... SAN JOSE, Calif. , Nov 16, 2015 ... leading developer of human interface solutions, today announced ... new Synaptics TouchView ™ touch controller and ... the architectural revolution of smartphones. These new TDDI ... and include TD4100 (HD resolution), TD4302 (WQHD resolution), ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
Breaking Biology News(10 mins):